Date Title  
Feb 14, 2020
Summary ToggleSol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares
 
Feb 13, 2020
Summary ToggleSol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks
 
Feb 05, 2020
Summary ToggleSol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020
 
Jan 21, 2020
Summary ToggleSol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
 
Jan 08, 2020
Summary ToggleSol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne Vulgaris
 
Jan 02, 2020
Summary ToggleSol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)
 
Dec 30, 2019
Summary ToggleSol-Gel Announces Positive Top-Line Phase 3 Trial Results of Twyneo® for the Treatment of Acne Vulgaris
 
Nov 13, 2019
Summary ToggleSol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update
 
Oct 16, 2019
Summary ToggleSol-Gel to Present on Potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
 
Aug 13, 2019
Summary ToggleSol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update
 
Displaying 11 - 20 of 52 results